These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28283157)

  • 1. AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report.
    Golden DBK; Bernstein DI; Freeman TM; Tracy JM; Lang DM; Nicklas RA
    J Allergy Clin Immunol Pract; 2017; 5(2):330-332. PubMed ID: 28283157
    [No Abstract]   [Full Text] [Related]  

  • 2. Limited ability of recombinant Hymenoptera venom allergens to resolve IgE double sensitization.
    Šelb J; Bidovec Stojković U; Bajrović N; Kopač P; Eržen R; Zidarn M; Košnik M; Korošec P
    J Allergy Clin Immunol Pract; 2018; 6(6):2118-2120. PubMed ID: 29802909
    [No Abstract]   [Full Text] [Related]  

  • 3. AAAAI/ACAAI Joint Venom Extract Shortage Task Force Report.
    Golden DB; Bernstein DI; Freeman TM; Tracy JM; Lang DM; Nicklas RA
    Ann Allergy Asthma Immunol; 2017 Mar; 118(3):283-285. PubMed ID: 28284534
    [No Abstract]   [Full Text] [Related]  

  • 4. Hymenoptera Anaphylaxis as a Clonal Mast Cell Disorder.
    Bonadonna P; Scaffidi L
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):455-468. PubMed ID: 30007463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venom immunotherapy in patients with allergic reactions to insect stings.
    Incorvaia C; Mauro M; Gritti BL; Makri E; Ridolo E
    Expert Rev Clin Immunol; 2018 Jan; 14(1):53-59. PubMed ID: 29202591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facing Hymenoptera Venom Allergy: From Natural to Recombinant Allergens.
    Perez-Riverol A; Justo-Jacomini DL; Zollner Rde L; Brochetto-Braga MR
    Toxins (Basel); 2015 Jul; 7(7):2551-70. PubMed ID: 26184309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desensitisation to liposomal amphotericin B.
    Shadur B; Trahair TN; O'Brien T; Russell SJ; Ziegler JB
    J Allergy Clin Immunol Pract; 2017; 5(1):181-183. PubMed ID: 27743834
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients.
    Niedoszytko M; Bonadonna P; Oude Elberink JN; Golden DB
    Immunol Allergy Clin North Am; 2014 May; 34(2):365-81. PubMed ID: 24745680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular diagnosis and immunotherapy.
    Sastre J; Sastre-Ibañez M
    Curr Opin Allergy Clin Immunol; 2016 Dec; 16(6):565-570. PubMed ID: 27685663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-related clinical aspects in insect venom anaphylaxis.
    Nittner-Marszalska M; Liebhart J; Dor-Wojnarowska A
    Int J Immunopathol Pharmacol; 2015 Jun; 28(2):187-93. PubMed ID: 26078379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stinging insect allergy: state of the art 2015.
    Tankersley MS; Ledford DK
    J Allergy Clin Immunol Pract; 2015; 3(3):315-22; quiz 323. PubMed ID: 25956310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase.
    Stoevesandt J; Hain J; Stolze I; Kerstan A; Trautmann A
    Clin Exp Allergy; 2014; 44(5):747-55. PubMed ID: 24447144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of clinical effectiveness of Hymenoptera venom immunotherapy.
    Ruëff F; Vos B; Oude Elberink J; Bender A; Chatelain R; Dugas-Breit S; Horny HP; Küchenhoff H; Linhardt A; Mastnik S; Sotlar K; Stretz E; Vollrath R; Przybilla B; Flaig M
    Clin Exp Allergy; 2014; 44(5):736-46. PubMed ID: 24447114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When can immunotherapy for insect sting allergy be stopped?
    Müller UR; Ring J
    J Allergy Clin Immunol Pract; 2015; 3(3):324-8; quiz 329-30. PubMed ID: 25956311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of controlled sting challenge and component-resolved diagnosis in the success of venom immunotherapy.
    Dalmau Duch G; Gázquez García V; Gaig Jané P; Galán Nieto A; Monsalve Clemente RI
    J Investig Allergol Clin Immunol; 2012; 22(2):135-6. PubMed ID: 22533237
    [No Abstract]   [Full Text] [Related]  

  • 16. Changing practice: no need to stop ACE inhibition for venom immunotherapy.
    Slade CA; Douglass JA
    Clin Exp Allergy; 2014; 44(5):617-9. PubMed ID: 24734926
    [No Abstract]   [Full Text] [Related]  

  • 17. High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience.
    Bilò MB; Kamberi E; Tontini C; Marinangeli L; Cognigni M; Brianzoni MF; Garritani MS; Antonicelli L
    J Allergy Clin Immunol Pract; 2016; 4(2):327-9.e1. PubMed ID: 26563675
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro diagnosis of Hymenoptera venom allergy and further development of component resolved diagnostics.
    Ebo DG; Van Vaerenbergh M; de Graaf DC; Bridts CH; De Clerck LS; Sabato V
    Expert Rev Clin Immunol; 2014 Mar; 10(3):375-84. PubMed ID: 24490811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Honeybee venom immunotherapy: certainties and pitfalls.
    Bilò MB; Antonicelli L; Bonifazi F
    Immunotherapy; 2012 Nov; 4(11):1153-66. PubMed ID: 23194365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard.
    Larenas-Linnemann DE; Finegold I; Nelson H
    Ann Allergy Asthma Immunol; 2012 Jul; 109(1):6-9. PubMed ID: 22727150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.